OverviewSuggest Edit

Corcept Therapeutics is a pharmaceutical company which discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome. The Company is also developing Korlym in different combinations to treat patients with triple-negative breast cancer and metastatic castration-resistant prostate cancer. In addition, it develops product candidates for the treatment of Cushing's syndrome and solid-tumor cancers.

TypePublic
Founded1998
HQMenlo Park, US
Websitecorcept.com
Employee Ratings3.7

Latest Updates

Employees (est.) (Dec 2019)206(+25%)
Job Openings6
Revenue (FY, 2019)$306.5 M(+22%)
Share Price (Sept 2020)$17.8
Cybersecurity ratingBMore

Key People/Management at Corcept Therapeutics

Joseph K. Belanoff

Joseph K. Belanoff

Director
James N Wilson

James N Wilson

Chairman of the Board
Joseph K Belanoff

Joseph K Belanoff

Chief Executive Officer, President, and Director
Andreas Grauer

Andreas Grauer

Chief Medical Officer
Hazel Hunt

Hazel Hunt

Senior Vice President, Research
Sean Maduck

Sean Maduck

Senior Vice President, Commercial
Show more

Corcept Therapeutics Office Locations

Corcept Therapeutics has an office in Menlo Park
Menlo Park, US (HQ)
149 Commonwealth Dr
Show all (1)

Corcept Therapeutics Financials and Metrics

Corcept Therapeutics Revenue

Corcept Therapeutics's revenue was reported to be $306.49 m in FY, 2019
USD

Revenue (Q2, 2020)

88.6m

Gross profit (Q2, 2020)

87.3m

Gross profit margin (Q2, 2020), %

98.6%

Net income (Q2, 2020)

28.3m

EBIT (Q2, 2020)

35.3m

Market capitalization (22-Sept-2020)

2.1b

Closing stock price (22-Sept-2020)

17.8

Cash (30-Jun-2020)

58.5m

EV

2.0b
Corcept Therapeutics's current market capitalization is $2.1 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

3.3m10.4m26.6m50.3m81.3m159.2m251.2m306.5m

Revenue growth, %

156%89%62%

Cost of goods sold

91.0k143.0k882.0k1.4m2.1m3.6m5.2m5.5m

Gross profit

3.2m10.2m25.7m48.9m79.3m155.6m246.0m301.0m
Quarterly
USDQ2, 2011

Financial Leverage

1.1 x
Show all financial metrics

Corcept Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

80/100

SecurityScorecard logo

Corcept Therapeutics Online and Social Media Presence

Embed Graph

Corcept Therapeutics News and Updates

Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant in Patients with Cushing’s Syndrome of Adrenal Origin

MENLO PARK, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced…

Corcept Therapeutics Appoints Gregg Alton to Board of Directors

MENLO PARK, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone corti…

Corcept Therapeutics Appoints Kimberly Park to Board of Directors

MENLO PARK, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone corti…

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Corcept Therapeutics Incorporated To Contact The Firm

NEW YORK, April 11, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Corcept Therapeutics Incorporated ("Corcept" or the "Company")(NASDAQ: CORT) of the May 13, 2019 deadline to seek the role of lead plaintiff in a federal securities...

Hagens Berman Reminds Corcept Therapeutics (CORT) Investors of May 13, 2019 Lead Plaintiff Deadline

San Francisco - Hagens Berman Sobol Shapiro LLP reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) of the May 13, 2019 Lead Plaintiff deadline in the pending securities class action.  If you purchased or otherwise acquired Corcept Therapeutics securities between August 2, 2017 and…

CORT Class Action Alert: Hagens Berman Alerts Corcept Therapeutics (NASDAQ: CORT) Investors to Securities Class Action and May 13, 2019 Lead Plaintiff Deadline

SAN FRANCISCO, March 19, 2019 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) to the May 13, 2019 Lead Plaintiff deadline in the securities class action pending in the United States District Court for the Northern...
Show more

Corcept Therapeutics Blogs

Corcept Therapeutics Announces First Quarter 2020 Financial Results And Provides Corporate Update

Corcept Therapeutics Announces First Quarter 2020 Financial Results And Provides Corporate Update Content Import Mon, 05/04/2020 - 16:07 Corcept Therapeutics Announces First Quarter 2020 Financial Results And Provides Corporate Update May 4, 2020 at 4:05 PM EDT …

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call Content Import Mon, 04/27/2020 - 16:05 Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call Apri…

Corcept Therapeutics Publishes Abstract in the Journal of the Endocrine Society

Corcept Therapeutics Publishes Abstract in the Journal of the Endocrine Society kevindavis Wed, 04/01/2020 - 08:31 Corcept Therapeutics Publishes Abstract in the Journal of the Endocrine Society April 1, 2020 at 8:30 AM EDT This release is a backfill from a Ne…

Corcept Therapeutics Announces Fourth Quarter And Full-Year 2019 Audited Financial Results And Provides Corporate Update

Corcept Therapeutics Announces Fourth Quarter And Full-Year 2019 Audited Financial Results And Provides Corporate Update Content Import Thu, 02/20/2020 - 16:06 Corcept Therapeutics Announces Fourth Quarter And Full-Year 2019 Audited Financial Results And Provides Corporate Update …

Corcept Therapeutics to Announce Audited Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics to Announce Audited Financial Results, Provide Corporate Update and Host Conference Call Content Import Thu, 02/13/2020 - 16:05 Corcept Therapeutics to Announce Audited Financial Results, Provide Corporate Update and Host Conference Call February 13, 202…

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2019 Preliminary Selected Financial Results; Provides 2020 Revenue Guidance

2019 revenue of $306.5 million , an increase of 22 percent from 2018 Fourth quarter revenue of $87.9 million , an increase of 32 percent from fourth quarter 2018 Cash and investments at December 31, 2019 , of $315.3 million 2020 revenue guidance of $355 - 375 million Advancing development of
Show more

Corcept Therapeutics Frequently Asked Questions

  • When was Corcept Therapeutics founded?

    Corcept Therapeutics was founded in 1998.

  • Who are Corcept Therapeutics key executives?

    Corcept Therapeutics's key executives are Joseph K. Belanoff, James N Wilson and Joseph K Belanoff.

  • How many employees does Corcept Therapeutics have?

    Corcept Therapeutics has 206 employees.

  • What is Corcept Therapeutics revenue?

    Latest Corcept Therapeutics annual revenue is $306.5 m.

  • What is Corcept Therapeutics revenue per employee?

    Latest Corcept Therapeutics revenue per employee is $1.5 m.

  • Who are Corcept Therapeutics competitors?

    Competitors of Corcept Therapeutics include Insys Therapeutics, Regeneron Pharmaceuticals and ASLAN Pharmaceuticals.

  • Where is Corcept Therapeutics headquarters?

    Corcept Therapeutics headquarters is located at 149 Commonwealth Dr, Menlo Park.

  • Where are Corcept Therapeutics offices?

    Corcept Therapeutics has an office in Menlo Park.

  • How many offices does Corcept Therapeutics have?

    Corcept Therapeutics has 1 office.